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Abstract
One essential task in information extraction from the medical corpus is drug name
recognition. Compared with text sources come from other domains, the medical text is
special and has unique characteristics. In addition, the medical text mining poses more
challenges, e.g., more unstructured text, the fast growing of new terms addition, a wide
range of name variation for the same drug. The mining is even more challenging due to
the lack of labeled dataset sources and external knowledge, as well as multiple token
representations for a single drug name that is more common in the real application
setting. Although many approaches have been proposed to overwhelm the task, some
problems remained with poor F-score performance (less than 0.75). This paper presents
a new treatment in data representation techniques to overcome some of those challenges.
We propose three data representation techniques based on the characteristics of word
distribution and word similarities as a result of word embedding training. The first
technique is evaluated with the standard NN model, i.e., MLP (Multi-Layer
Perceptrons). The second technique involves two deep network classifiers, i.e., DBN
(Deep Belief Networks), and SAE (Stacked Denoising Encoders). The third technique
represents the sentence as a sequence that is evaluated with a recurrent NN model, i.e.,
LSTM (Long Short Term Memory). In extracting the drug name entities, the third
technique gives the best F-score performance compared to the state of the art, with its
average F-score being 0.8645.
Keywords— drug name entity, word embedding, MLP, DBN, SAE, LSTM
Introduction
The rapid growth of information technology provides rich text data resources in all
areas, including the medical field. An abundant amount of medical text data can be
used to obtain valuable information for the benefit of many purposes. The
understanding of drug interactions, for example, is an important aspect of
manufacturing new medicines or controlling drug distribution in the market. The
process to produce a medicinal product is an expensive and complex task. In many
recent cases, however, many drugs are withdrawn from the market when it was
discovered that the interaction between the drugs is hazardous to health [27].
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Information, or objects extraction, from an unstructured text document, is one of
the most challenging studies in the text mining area. The difficulties of text information
extraction keeps increasing due to the increasing size of corpora, continuous growth of
human’s natural language, and the unstructured formatted data [33]. Among such
valuable information are medical entities such as drug name, compound, and brand;
disease name, and their relations, such as drug - drug interaction and drug - compound
relation. We need a suitable method to extract such information. To embed those
abundant data resources; however, many problems have to be tackled. For example,
large data size, unstructured format, choosing the right NLP, and the limitation of
annotated datasets.
A more specific and valuable information contained in medical text data is a drug
entity (drug name). Drug name recognition is a primary task of medical text data
extraction since the drug finding is the essential element in solving other information
extraction problems [18,37]. Among derivative work of drug name extractions are
drug-drug interaction [12], drug adverse reaction [29], or other applications (information
retrieval, decision support system, drug development or drug discovery) [32].
Compared to other NER (Named-Entity Recognition) tasks, such as PERSON,
LOCATION, EVENT, or TIME, drug name entity recognition faces more challenges.
First, the drug name entities are usually unstructured texts [17] where the number of
new entities is quickly growing over time. Thus, it is hard to create a dictionary which
always includes the entire lexicon and is up to date [25]. Second, the naming of the drug
also widely varies. The abbreviation and acronym increase the difficulties in
determining the concepts referred by the terms. Third, many drug names contain a
combination of non-word and word symbols [20].Fourth, the other problem in drug name
extraction is that a single drug name might be represented by multiple tokens [10]. Due
to the complexity in extracting multiple tokens for drugs, some researchers such as [2]
even ignores that case in the MedLine & DrugBank training with the reason that the
multiple tokens drug is only 18% of all drug names. It is different with another domain,
i.e., entity names in the biomedical field are usually longer. Fifth, in some cases, the
drug name is a combination of medical and general terms. Sixth, the lack of the labeled
dataset is another problem; it has yet to be solved by extracting the drug name entities.
This paper presents three data representation techniques to extract drug name
entities contained in the sentences of medical texts. For the first and the second
techniques, we created an instance of the dataset as a tuple, which is formed from 5
vectors of words. In the first technique, the tuple was constructed from all sentences
treated as a sequence, whereas in the second technique the tuple is made from each
sentence treated as a sequence. The first and second techniques were evaluated with the
standard MLP-NN model which is perfomed in the first experiment. In the second
experiment, we use the second data representation technique which is also applied to
the other NN model i.e. DBN and SAE. The third data representation, which assumes
the text as sequential entities, was assessed with the recurrent NN model, LSTM. Those
three data representation techniques are based on the word2vec value characteristics,
i.e., their cosine and the Euclidean distance between the vectors of words.
In the first and second techniques, we apply three different scenarios to select the
most possible words which represent the drug name. The scenarios are based on the
characteristics of training data, i.e., drug words distribution that is usually assumed has
a smaller frequency of appearance in the dataset sentences. The drug name candidate
selections are as follows. In the first case, all test dataset is taken. In the second case,
2/3 of all test dataset is selected. In the third case, x/y(x < y) of the test dataset
(where x and y are arbitrary integer numbers) are selected after clustering the test
dataset into y clusters.
In the third experiment, based on the characteristics of the resulting word vectors of
2/25
the trained word embedding, we formulate a sequence data representation which applied
to RNN-LSTM. We used the Euclidian distance of the current input to the previous
input as an additional feature besides its vector of words. In this study, the vector of
words is provided by word embedding methods proposed by Mikolov [21].
Our main important contributions in this study are:
1. The new data representation techniques which do not require any external
knowledge nor hand-crafted features.
2. The drug extraction techniques based on the words distribution contained in the
training data.
Our proposed method is evaluated on DrugBank and MedLine medical open dataset
obtained from SemEval 2013 Competition task 9.1, see
http://www.cs.york.ac.uk/semeval-2013/task9.html, which is also used by [1, 2, 10]. The
format of both medical texts is in English where some sentences contain drug name
entities. In extracting drug entity names from the dataset, our data representation
techniques give the best performance with F-score values 0.687 for MLP, 0.6700 for
DBN, and 0.682 for SAE, whereas the third technique with LSTM gives the best
F-score, i.e., 0.9430. The average F-score of the third technique is 0.8645, i.e., the best
performance compared to the other previous methods.
By applying the data representation techniques, our proposed approach provides at
least three advantages:
1. The capability to identify multiple tokens as a single name entity.
2. The ability to deal with the absence of any external knowledge in certain
languages.
3. No need to construct any additional features, such as characters type
identification, orthography feature (lowercase or uppercase identification), or
token position.
The rest sections of this paper are organized as follow: Section 1 explain some
previous works dealing with name entity (and drug name as well) extraction from
medical text sources. The framework, approach, and methodology to overcome the
challenges of drug name extraction is presented in the Section 2. The section also
describes dataset materials and experiment scenarios. Section 3 discusses the
experiment results and its analysis while section 4 explains the achievement, the
shortcoming, and the prospects of this study. The section also describes several
potential explorations for future research.
1 Related Works
The entity recognition in a biomedical text is an active research, and many methods
have been proposed. For example, Gurinder et al. [25] summarizes their survey on
various entity recognition approaches. The approaches can be categorized into three
models: dictionary based, rule based, and learning based methods [17, 33]. A dictionary
based approach uses a list of terms (term collection) to assist in predicting which
targeted entity will be included in the predicted group. Although their overall precision
is more accurate, their recall is poor since they anticipate less new terms. The
rule-based approach defines a certain rule which describes such pattern formation
surrounding the targeted entity. This rule can be a syntactic term or lexical term.
Finally, the learning approach is usually based on statistical data characteristics to
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build a model using machine learning techniques. The model is capable of automatically
learn based on positive, neutral, and negative training data.
Drug name extraction and their classification are one of the challenges in the
Semantic Evaluation Task (SemEval 2013). The best-reported performance for this
challenge was 71.5% in F-score [31]. Until now the studies to extract drug names still
continue and many approaches have been proposed. CRF-based learning is the most
common method utilized in the clinical text information extraction. CRF is used by one
of the best [10] participants in SemEval challenges in the clinical text
(https://www.cs.york.ac.uk/semeval-2013). As for the use of external knowledge aimed
to increase the performance, the author [10] uses ChEBI (Chemical Entities of
Biological Interest), i.e., a dictionary of small molecular entities. The best-achieved
performance is 0.57 in F-score (for the overall dataset).
A hybrid approach model, which combines statistical learning and dictionary based,
is proposed by [30]. In their study, the author utilizes word2vec representation, CRF
learning model and DINTO, a drug ontology. With this word2vec representation,
targeted drug is treated as a current token in a context windows which consists of three
tokens on the left and three tokens in the right. Additional features are included in the
data representation such as pos tags, lemma in the windows context, an orthography
feature as uppercase, lowercase, and mixed cap. The author also used Wikipedia text as
an additional resource to perform word2vec representation training. The best F-score
value in extracting the drug name provided by the method is 0.72.
The result of a CRF based active learning, which is applied to NER BIO (Beginning,
Inside, Output) annotation token for extracting named entity in the clinical text, is
presented in [6]. The framework of this active learning approach is a sequential process:
initial model generation, querying, training, and iteration. The CRF Algorithm BIO
approach was also studied by A. Ben et al. [1]. The features for the CRF algorithm is
formulated based on token and linguistics feature and semantic feature. The best
F-score achieved by this proposed method is 0.72.
Korkontzelos et al. studied a combination of aggregated classifier, maximum
entropy-multinomial classifier, and handcrafted feature to extract drug entity. [18].They
classified drug and non-drug based on the token features formulation such as tokens
windows, the current token, and 8 other hand-crafted features.
Another approach for discovering valuable information from clinical text data that
adopts event-location extraction model was examined by J, Bjornoe et al. [2]. They use
an SVM classifier to predict drug or non-drug entity which is applied to DrugBank
dataset. The best performance achieved by their method is a 0.6 in F-score. The
drawback of their approach is that it only deals with a single token drug name.
To overcome the ambiguity problem in NER mined from a medical corpus, a
segment representation method has also been proposed by S. Keretna et al. [17]. Their
approach treats each word as belonging to three classes, i.e., NE, not NE and an
ambiguous class. The ambiguity of the class member is determined by identifying
whether the word appears in more than one context or not. If so, this word falls into
the ambiguous class. After three class segments are found, it is then applied to the
classifier learning. Related to their approach, in our previous work, we propose a
pattern learning that utilizes the regular expression surrounding drug names and their
compounds [28]. The performance of our method is quite good with the average F-score
being 0.81 but has a limitation in dealing with more unstructured text data.
In summarizing the related previous works on drug name entity extraction, we noted
some drawbacks which need to be addressed. In general, almost all state of the art
methods works based on ad-hoc external knowledge which is not always available. The
requirement of the handcrafted feature is another difficult constraint since not all
datasets contain such feature. An additional challenge that remained unsolved by the
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Figure 1. Proposed approach framework of the first experiment
previous works is the problem of multiple tokens representation for a single drug name.
This study proposes a new data representation technique to handle those challenges.
Our proposed method is based only on the data distribution pattern and vector of
words characteristics, so there is no need for external knowledge nor additional
handcrafted features. To overcome the multiple tokens problem, we propose a new
technique which treats a target entity as a set of tokens (a tuple) at once rather than
treating the target entity as a single token surrounded by other tokens such as used
by [30] or [4]. By addressing a set of the tokens as a single sample, our proposed
method can predict whether a set of tokens is a drug name or not. In our first
experiment, we evaluate the first and second data representation techniques and apply
MLP learning model. In our second scenario, we choose the the second technique which
gave the best result with MLP, and apply it to two different machine learning methods:
DBN, and SAE. In our third experiment, we examined the third data representation
technique which utilizes the Euclidian distance between successive words in a certain
sentence of medical text. The third data representation is then fed into an LSTM model.
Based on the resulted F-score value, the second experiment gives the best performance.
2 Method & Material
2.1 Framework
In this study, using the word2vec value characteristics, we conducted three experiments
based on different data representation techniques. The first and second experiment
examine conventional tuple data representation, whereas the third experiment examines
sequence data representation. We describe the organization of these three experiments
in this Section. In general, the proposed method to extract drug name entities in this
study consists of two main phases. The first phase is a data representation to formulate
the feature representation. In the second phase, model training, testing, and their
evaluation is then conducted to evaluate the performance of the proposed method.
The proposed method of the first experiment consists of 4 steps (see Figure 1). The
first step is a data representation formulation. The output of the first step are the
tuples of training and testing dataset. The second step is dataset labeling which is
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Figure 2. Proposed approach framework of the second experiment
applied to both testing and training data. The step provides the label of each tuple.
The third step is the candidate selection which is performed to minimize the noises since
the actual drug target quantity is a far less compared to nondrug name. In the last step,
we performed the experiment with MLP-NN model and its result evaluation. The
detailed explanation of each step is explained in the Subsection 2.4, 2.6, and 2.9,
whereas section 2.2 and 2.3 describe training data analysis as the foundation of this
proposed method. As a part of the first experiment, we also evaluate the impact of the
usage of the Euclidean distance average as the model’s regularization. This
regularization term is described in the Subsection 2.7.1.
The framework of the second experiment which involves DBN and SAE learning
model to the second data representation technique is illustrated in Figure 2. In general,
the steps of the second experiment is similar to the first one, with its differences are the
data representation used and the learning model involved. In the second experiment, it
is used the second technique only with DBN and SAE as the learning model.
The framework of the third experiment using the LSTM is illustrated in Figure 3.
There are tree steps in the third experiment. The first step is sequence data
representation formulation which provides both sequence training data and testing data.
The second step is data labeling which generates the label of training and testing data.
LSTM experiment and its result evaluation are performed in the third step. The detail
description of these tree step are presented in Subsection 2.4, 2.4.3, and Subsection 2.9
as well.
2.2 Training Data Analysis
Each of the sentences in the dataset contains four data types i.e. drug, group, brand,
and drug-n. If the sentence contains none of those four types, the type value is null. In
the study, we extracted drug and drug-n. Overall in both DrugBank and MedLine
datasets, the quantity of drug name target is far less compared to the non-drug target.
Segura et al. [31] present the first basic statistics of the dataset. A more detailed
exploration regarding token distribution in the training dataset is described in this
section. The MedLine sentences training dataset contains 25.783 single token, which
consists of 4.003 unique tokens. Those tokens distributions are not uniform, but are
dominated by a small part of some unique tokens. If all of the unique tokens are
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Figure 3. Proposed approach framework of the third experiment
arranged and ranked based on the most frequent appearances in the sentences, the
quartile distribution will have the following result presented in Figure 4. Q1 represents
the token number 1 to 1001 which their total of frequency is 20.688. Q2 represents the
token number 1002 to 2002 which their total of frequency is 2.849. Q3 represents the
token number 2003 to 3002 which their total of frequency is 1.264, and Q4 represents
the token number 3003 to 4003 which their total of frequency is 1.000. The Figure
shows that the majority appearances are dominated by only a small amount of the total
tokens.
Further analysis of the dataset tokens shows that most of the drug names of the
targeted token rarely appear in the dataset. When we divide those token collections into
three partitions based on their sum of frequency, as presented in Table 1, it is shown
that all of the drug name entity targeted are contained in 2/3 part with less frequent
appearances of each token (a unique token in the same sum of frequency). The similar
pattern of training data token distribution also emerged in the DrugBank dataset as
illustrated in Figure 5 and Table 2. When we look into specific token distributions, the
position of most of drug name target are in the third part. Since the most frequently
appeared words in the first and the second parts are the most common words such as:
stop words (”of”, ”the”, ”a”, ”end”, ”to”, ”where”, ”as”, ”from”, and such kind of
words) and common words in medical domain such as ”administrator”, ”patient”,
”effect”, ”dose”, etc.
Table 1. The frequency distribution & drug target token position, MedLine
1/3# Σ Sample Σ Frequency Σ Single Token of Drug Entity
1 28 8,661 -
2 410 8,510 50
3 3,563 8,612 262
Table 2. The frequency distribution & drug target token position, DrugBank
1/3# Σ Sample Σ Frequency Σ Single Token of Drug Entity
1 27 33,538 -
2 332 33,463 33
3 5,501 33,351 920
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Figure 4. Distribution of MedLine train dataset token
Figure 5. Distribution of DrugBank train dataset token
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2.3 Word Embedding Analysis
To represent the dataset we utilized the word embedding model proposed by Mikolov et
al. [21]. We treated all of the sentences as a corpus after the training dataset and
testing dataset were combined. The used word2vec training model was the CBOW
(Continuous Bag Of Words) model with context window length 5, and the vector
dimension 100. The result of the word2vec training is the representation of word in 100
dimension row vectors. Base on the row vector, it can be estimated the similarities or
dissimilarities between words. The description below is the analysis summary of
word2vec representation result which is used as a base reference for the data
representation technique and the experiment scenarios. By taking some sample of drug
targets and non-drug vector representation, it is shown that drug word has more
similarities (cosine distance) to another drug than to non-drug and the vice versa. Some
of those samples are illustrated in Table 3. We also computed the Euclidean distance
between all of the words. Table 4 shows the average of Euclidean distance and cosine
distance between drug-drug, drug - non-drug, and non-drug - non-drug. These values of
the average distance show us that, intuitively, it is feasible to group the collection of the
word into drug group and non-drug group based on their vector representations value.
Table 3. Some of the cosines-distance similarities between two kinds of words
word 1 word 2 similarities(cosine-dist) remark
dilantin tegretol 0.75135758 drug-drug
phenytoin dilantin 0.62360351 drug-drug
phenytoin tegretol 0.51322415 drug-drug
cholestyramine dilantin 0.24557819 drug-drug
cholestyramine phenytoin 0.23701277 drug-drug
administration patients 0.20459694 non-drug - non-drug
tegretol may 0.11605539 drug - non-drug
cholestyramine patients 0.08827197 drug - non-drug
evaluated end 0.07379115 non-drug - non-drug
within controlled 0.06111103 non-drug - non-drug
cholestyramine evaluated 0.04024139 drug - non-drug
dilantin end 0.02234770 drug - non-drug
Table 4. The average of euclidean-distance and cosine similarities between groups of
word
Word Group Euclidean Dist. avg Cosine Dist. avg
drug - non-drug 0.096113798 0.194855980
non-drug - non-drug 0.094824332 0.604091044
drug-drug 0.093840800 0.617929002
2.4 Feature Representation, Data Formatting, & Data
Labelling
Based on the training data and word embedding analysis, we formulate the feature
representation and its data formatting. In the first and second techniques, we try to
overcome the multiple tokens drawback that left unsolved in [2] by formatting a single
input data as an N - gram model with N=5 (one tuple data consist 5 tokens) to
accommodate the maximum token which acts as a single drug entity target name. The
tuples were provided from the sentences of both training and testing data. Thus, we
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have a set of tuples of training data and a set of tuples of testing data. Each tuple was
treated as a single input.
Result: Labelled dataset
Input:array of tuple, array of drug ;
output: array of label {Array of drug contains list of drug and drug-n only} ;
label[]<=1 Initialization;
for each t in tuple do
for each d in drug do
if length (d) = 1 then
if t[1] = d[1] then
//match 1 token drug;
label <= 2, break, exit from for each d in drug;
else
end
else
if length (d) = 2 then
if t[1] = d[1] and t[2] = d[2] then
//match 2 tokens drug;
label <= 3, break, exit from for each d in drug;
else
end
else
if length (d) = 3 then
if t[1] = d[1] and t[2] = d[2] and t[3] = d[3] then
label <= 4, break, exit from for each d in drug;
else
end
else
if length (d) = 4 then
if t[1] = d[1] and t[2] = d[2] and t[3] = d[3] and t[4] = d[4] then
label <= 5, break, exit from for each d in drug;
else
end
else
if length (d) = 5 then
if t[1] = d[1] and t[2] = d[2] and t[3] = d[3] and t[4] = d[4] and
t[5] = d[5] then
label <= 6, break, exit from for each d in drug;
else
end
else
end
end
end
end
end
end
end
Algorithm 1: Dataset Labelling
To identify a single input, whether it is a non-drug or drug target, we use a
multi-classification approach which classifies the single input into one of six classes.
class 1 represents non-drug whereas the other classes represent drug target which also
identified how many tokens (word) that perform the drug target. To identify which
class a certain tuple belongs to is determined as follows: The drug tuple is the tuple
which its first token (token-1) is the drug type. If the token-1 is not a drug, regardless
of whatever the rest of the 4 tokens are, then the tuple is classified as no drug. This
kind of tuple is identified as class 1. If the token-1 is a drug, and token-2 is not a drug,
regardless of the last 3 tokens, the tuple will be identified as class 2, and so on.
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Since we only extracted the drug entity, we ignored the other token types, whether it
is a group, brand, or another common token. To provide the label of each tuple, we only
use the drug and drug-n types as the tuple reference list. In general, if the sequence of
token in each tuple in dataset contains the sequence which is exactly same with one of
tuple reference list members, then the tuple in dataset is identified as drug entity. The
detail of the algorithm used to provide the label of each tuple in both training data and
testing data is described in Algorithm 1:
We proposed two techniques in constructing the tuple set of the sentences. The first
technique treats all sentences as one sequence, whereas in the second technique, each
sentence is processed as one sequence. The first and the second techniques are evaluated
with MLP, DBN, and SAE model. The third technique treats the sentences of dataset
as a sequence where the occurrence of the current token is influenced by the previous
one. By treating the sentence as a sequence not only in the data representation but also
in the classification and recognition process, the most suitable model to be used is RNN.
We applied RNN-LSTM to the third technique.
2.4.1 First Technique
The first dataset formatting (one sequence for all sentences) is performed as follows. In
the first step, all sentences in the dataset are formatted as a token sequence. Let the
token sequence is:
t1t2t3t4t5t6t7t8...tn
with n is number of token in the sequences, then the dataset format will be:
t1t2t3t4t5; t2t3t4t5t6; . . . ..tn−4tn−3tn−2tn−1tn;
A sample of sentences and their drug name are presented in Table 5.Taken from
DrugBank training data Table 5 is the raw data of 3 samples with three relevant fields,
i.e., sentences, character drug position, and the drug name. Table 6 illustrates a portion
of the dataset and its label as the result of the raw data in Table 5. Refer to the drug-n
name field in the dataset, dataset number 6 is identified as a drug, whereas the others
are classified as a non-drug entity. The complete label illustration of the dataset
provided by the first technique is presented in Table 7. As described in the Section 2.4,
the value of vector dimension for each token is 100. Therefore, for a single data, it is
represented as 100*5 = 500 lengths of a one-dimensional vector.
Table 5. Sample of DrugBank sentences and their drug name target
Sentence Drug Drug
Position Name
modification of surface histidine clostridium
residues abolishes the cytotoxic 79-107 difficile
activity of clostridium difficile toxin a
toxin a
antimicrobial activity of ganoderma ganoderma
lucidum extract alone and in 26-50 lucidum
with some antibiotics. extract
on the other hand, surprisingly, green tea
green tea gallocatechins, gallocatechins
(-)-epigallocatechin-3-o-gallate and 33-56
theasinensin a, potently enhanced
the promoter activity (182 and 247%
activity at 1 microm, respectively).
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Table 6. A portion of the dataset formulation as the results of DrugBank sample with
first technique
dataset
Num-
ber
token-1 token-2 token-3 token-4 token-5 label
1 modification of surface histidine residues 1
2 of surface histidine residues abolishes 1
3 surface histidine residues abolishes the 1
4 histidine residues abolishes the cytotoxic 1
5 the cytotoxic activity of clostridium 1
6 clostridium difficile toxin a antimicrobial 5
7 difficile toxin a antimicrobial activity 1
Table 7. First Technique Data Representation and Its Label
token-1 token-2 token-3 token-4 token-5 label
’plenaxis’ ’were’ ’performed’ ’cytochrome’ ’p-450’ 2
’testosterone’ ’concentrations’ ’just’ ’prior’ ’to’ 2
’beta-
adrenergic’
’antagonists’ ’and’ ’alpha-
adrenergic’
’stimulants,’ 3
’carbonic’ ’anhydrase’ ’inhibitors,’ ’concomitant’ ’use’ 3
’sodium’ ’polystyrene’ ’sulfonate’ ’should’ ’be’ 4
’sodium’ ’acid’ ’phosphate’ ’such’ ’as’ 4
’clostridium’ ’difficile’ toxin’ a’ ’-’ 5
’nonsteroidal’ anti’ ’inflammatory’’drugs’ ’and’ 5
’casein’ ’phosphopeptide-
amorphous’
’calcium’ ’phosphate’ ’complex’ 6
’studies’ ’with’ ’plenaxis’ ’were’ ’performed.’ 1
’were’ ’performed.’ ’cytochrome’ ’p-450’ ’is’ 1
2.4.2 Second Technique
The second technique is used for treating one sequence that comes from each sentence of
the dataset. With this treatment, we added special characters ∗, as a padding, to the
last part of the token when its dataset length is less than 5. By applying the second
technique the first sentence of the sample provided a dataset as illustrated in Table 8.
Table 8. Second technique data representation and its label
token-1 token-2 token-3 token-4 token-5 label
’modification’ ’of’ ’surface’ ’histidine’ ’residues’ 1
’of’ ’surface’ ’histidine’ ’residues’ ’abolishes’ 1
surface histidine residues abolishes the 1
’histidine’ ’residues’ ’abolishes’ ’the’ ’cytotoxic’ 1
’the’ ’cytotoxic’ ’activity’ ’of’ ’clostridium’ 1
’clostridium’ ’difficile’ ’toxin’ ’a’ ’*’ 5
’difficile’ ’toxin’ ’a’ ’*’ ’*’ 1
’a’ ’atoxin’ ’*’ ’*’ ’*’ 1
’toxic’ ’*’ ’*’ ’*’ ’*’ 1
2.4.3 Third Technique
Naturally, the NLP sentence is a sequence in which the occurrence of the current word
is conditioned by the previous one. Based on the word2vec value analysis, it is shown
that intuitively we can separate the drug word and non-drug word by their Euclidean
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distance. Therefore, we used the Euclidean distance between the current words with the
previous one to represent the influence. Thus, each current input xi is represented by
[xvixdi] which is the concatenation of word2vec value xvi and its Euclidian distance to
the previous one, xdi. Each x is the row vector with the dimension length is 200, the
first 100 values are its word2vector, and the rest of all 100 values are the Euclidian
distance to the previous. For the first word all value of xdi is 0. With the LSTM model,
the task to extract the drug name from the medical data text is the binary classification
that applied to each word of the sentence. We formulate the word sequence and its class
as described in Table 9. In this experiment, each word that represents the drug name is
identified as class 1, such as ’plenaxis’, ’cytochrome’, and ’p-450,’ whereas the other
words are identified by class 0.
Table 9. Third technique of data representation and its label
Sent.#1
Class 0 0 0 0 1 0 0
Word ’drug’ ’interaction’ ’studies’ ’with’ ’plenaxis’ ’were’ ’performed’
Sent.#2
Class 1 1 0 0 0 0 0
Word ’cytochrome’ ’p-450’ ’is’ ’not’ ’known’ in’ ’the
2.5 Wiki Sources
In this study we also utilize Wikipedia as the additional text sources in word2vec
training as used by [30]. The Wiki text addition is used to evaluate the impact of the
training data volume in improving the quality of word’s vector.
2.6 Candidates Selection
The tokens as the drug entities target are only a tiny part of the total tokens. In
MedLine dataset, 171 of 2.000 token (less than ten %) are drugs, whereas in DrugBank,
the number of drug tokens are 180 of 5.252 [31]. So the major part of these tokens are
non-drug and other noises such as a stop word, and special or numerical characters.
Based on this fact, we propose a candidate selection step to eliminate those noises. We
examine two mechanisms in the candidate selection. The first is based on token
distribution. The second is formed by selecting x/y part of the clustering result of data
test. In the first scenario, we only used 2/3 of the token, which appears in the lower 2/3
part of the total token. This is presented in Table 1 and Table 2. Whereas, in the
second mechanism we selected x/y(x < y) which is a part of total token after the tokens
are clustered into y clusters.
2.7 Overview of NN Model
2.7.1 MLP
In the first experiment, we used multi-layer perceptron NN to train the model and
evaluate the performance [19]. Given a training set of m examples, then the overall cost
function can be defined as:
J(W, b) =
[
1
m
m∑
i=1
J(W, b;xi, yi)
]
+
λ
2
nl−1∑
l=1
sl∑
i=1
sl−1∑
j=1
(
W
(l)
ji
)2
(1)
J(W, b) =
[
1
m
m∑
i=1
(
1
2
∣∣∣∣∣
∣∣∣∣∣hwb(x(i))− yi
∣∣∣∣∣
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2)]
+
λ
2
nl−1∑
l=1
sl∑
i=1
sl−1∑
j=1
(
W
(l)
ji
)2
(2)
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In the definition of J(W, b), the first term is an average sum-of-squares error term,
whereas the second term is a regularization term which is also called a weight decay
term. In this experiment we use three kinds of regularization: #0, L0 with λ = 0, #1,
L1 with λ = 1, and #2 with λ = the average of Euclidean distance. We computed the
L2’s λ based on the word embedding vector analysis that drug target and non-drug can
be distinguished by looking at their Euclidean distance. Thus, for L2 regularization, the
parameter is calculated as:
λ =
1
n ∗ (n− 1)
n−1∑
i=1
n∑
j=i+1
dist(xi, xj) (3)
where dist(xi,xj) is the Euclidean distance of xi and xj .
The model training and testing are implemented by modifying the code from [26]
which can be downloaded at https://github.com/rasmusbergpalm/DeepLearnToolbox.
2.7.2 DBN
DBN is a learning model composed of two or more stacked RBM [8,14]. An RBM is an
undirected graph learning model which associates with a Markov Random Fields (MRF).
In the DBN, the RBM acts as feature extractor where the pre-training process provides
initial weights values to be fine-tuned in the discriminative process in the last layer.
The last layer may be formed by logistic regression or any standard discriminative
classifiers [8]. RBM was originally developed for binary data observation [7, 35]. It is a
popular type of unsupervised model for binary data [13,34]. Some derivative of RBM
models are also proposed to tackle a continuous/real values suggested in [5, 36].
2.7.3 SAE
An autoencoder (AE) neural network is one of the unsupervised learning algorithms.
The NN tries to learn a function h(w, x) ≈ x. The autoencoder NN architecture also
consists of input, hidden, and output layers. The particular characteristic of the
autoencoder is that the target output is similar to the input. The interesting structure
of the data is estimated by applying a certain constraint to the network, which limits
the number of hidden units. However, when the number of hidden units has to be
larger, it can be imposed with sparsity constraints on the hidden units [22]. The
sparsity constraint is used to enforce the average value of hidden unit activation
constrained to a certain value. As used in the DBN model, after we trained the SAE,
the trained weight was used to initialize the weight of NN for the classification.
2.7.4 RNN-LSTM
RNN (Recurrent Neural Network) is an NN, which considers the previous input in
determining the output of the current input. RNN is powerful when it is applied to the
dataset with a sequential pattern or when the current state input depends on the
previous one, such as the time series data, sentences of NLP. An LSTM network is
special kind of RNN which also consists of 3 layers, i.e., an input layer, a single
recurrent hidden layer, and an output layer [16]. The main innovation of LSTM is that
its hidden layer consists of one or more memory blocks. Each block includes one or
more memory cells. In the standard form, the inputs are connected to all of the cells
and gates, whereas the cells are connected to the outputs. The gates are connected to
other gates and cells in the hidden layer. The single standard LSTM is a hidden layer
with input, memory cell, and output gates [11,23].
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2.8 Dataset
To validate the proposed approach, we utilized DrugBank and MedLine open dataset,
which have also been used by previous researchers. Additionally, we used drug label
documents from various drug producers and regulator Internet sites located in Indonesia:
1. http://www.kalbemed.com/
2. http://www.dechacare.com/
3. http://infoobatindonesia.com/obat/, and
4. http://www.pom.go.id/webreg/index.php/home/produk/01.
The drug labels are written in Bahasa Indonesia, and their common contents are
drug name, drug components, indication, contra indication, dosage, and warning.
2.9 Evaluation
To evaluate the performance of the proposed method, we use common measured
parameters in data mining i.e., precision, recall, and F-score. The computation formula
of these parameters is as follows. Let C = {C1, C2, C3...Cn} is a set of the extracted
drug-name of this method, and K = {K1,K2,K3, ...Kl} is set of actual drug-name in
the document set D. Adopted from [28], the parameter computations formula are:
Precision(Ki, Cj) =
(TruePositive)
(TruePositive+ FalsePositive)
=
(||Ki ∩ Cj ||)
(||Cj ||) (4)
Recall(Ki, Cj) =
(TruePositive)
(TruePositive+ FalseNegative)
=
(||Ki ∩ Cj ||)
(||Ki||) (5)
where ‖Ki‖, ‖Cj‖, and ‖Ki ∩ Cj‖ denote the number of drug-name in K, in C, and in
both K and C respectively. The F-score value is computed by the below formula:
F − score(Ki, Cj) = (2 ∗ Precision(Ki, Cj) ∗Recall(Ki, Cj))
(TruePositive+ FalsePositive)
(6)
3 Results and Discussion
3.1 MLP Learning Performance
The following experiments are the part of the first experiment. These experiments are
performed to evaluate the contribution of the three regularization settings as described
in the Subsection 2.7.1 . By arranging the sentence in training dataset as 5-gram of
words, the quantity of generated sample is presented in Table 10. We do training and
testing of the MLP-NN learning model for all those test data compositions. The result
of model performances on both datasets, i.e., MedLine & DrugBank, in learning phase
is shown Figure 6 and Figure 7. The NN Learning parameters that are used for all
experiments are: 500 input nodes, two hidden layers where each layer has 100 nodes
with sigmoid activation, and 6 output nodes with softmax function; the learning rate =
1, momentum = 0.5; and epochs = 100. We used mini-batch scenario in the training
with the batch size is 100. The presented errors in Figure 6 and Figure 7 are the errors
for full batch, i.e., the mean errors of all mini batches.
The learning model performance shows different patterns between MedLine and
DrugBank datasets. For both datasets, L1 regularization tends to stabilize in the lower
iteration and its training error performance is always less than L0 or L2. The L0 and L2
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Figure 6. Full batch training error of MedLine dataset
training error performance pattern, however, shows a slight different behavior between
MedLine and DrugBank. For the MedLine dataset, L0 and L2 produce different results
for some of iterations. Whereas, the training error performance of L0 and L2 for
DrugBank are almost the same in every iteration. Different pattern results are probably
due to the variation in the quantity of training data. As illustrated in Table 10, the
volume of DrugBank training data is almost four times the volume of the MedLine
dataset. It can be concluded that, for larger dataset, the contribution of L2
regularization setting is not too significant in achieving better performance. For smaller
dataset (MedLine), however, the performance is better even after only few iterations.
Table 10. Dataset Composition
dataset Train
Test
All 2/3 Part Cluster
MedLine 26,500 10,360 6,673 5,783
DrugBank 100,100 2,000 1,326 1,933
3.2 Open Dataset Performance
In the Table 11, 12, 13, and 14, the numbering (1), (2) and (3) in the most left column
indicate the candidate selection technique with:
1. (1) : all data test are selected
2. (2) : 2/3 part of data test are selected, and
3. (3) : 2/3 part of 3 clusters for MedLine or 3/4 part of 4 cluster for DrugBank
3.2.1 MLP-NN Performance
In this first experiment, for two data representation techniques and three candidate
selection scenarios, we have six experiment scenarios. The result of the experiment
which applies the first data representation technique and three candidate selection
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Figure 7. Full batch training error of DrugBank dataset
scenarios is presented in Table 11. In computing the F-score, we only select the
predicted target which is provided by the lowest error (the minimum one). For MedLine
dataset, the best performance is shown by L2 regularization setting where the error is
0.041818, in third candidate selection scenario with F-score 0.439516, whereas the
DrugBank is achieved together by L0 and L1 regularization setting, with an error test of
0.0802, in second candidate selection scenario, the F-score was 0.641745. Overall, it can
be concluded that DrugBank experiments give the best F-score performance. The
candidate selection scenarios also contributed to improving the performance, as we
found for both of MedLine and DrugBank, the best achievement is provided by the
second and third scenarios respectively.
Table 11. The F-score performances of three of scenarios experiments
MedLine Prec Rec F-score Lx error Test
(1) 0.3564 0.5450 0.4310 L0 0.0305
(2) 0.3806 0.5023 0.4331 L1,L2 0.0432
(3) 0.3773 0.5266 0.4395 L2 0.0418
DrugBank Prec Rec F-score Lx error Test
(1) 0.6312 0.5372 0.5805 L0 0.07900
(2) 0.6438 0.6398 0.6417 L0,L2 0.0802
(3) 0.6305 0.5380 0.5806 L0 0.0776
The next experimental scenario in the first experiment is performed to evaluate the
impact of the data representation technique and the addition of Wiki source in
word2vec training. The results are presented in Table 12 and Table 13. According to
the obtained results presented in Table 11, the L0 regularization gives the best F-score.
Hence, accordingly we only used the L0 regularization for the next experimental
scenario. The table 12 presents the impact of the data representation technique.
Looking at the F-score, the second technique gives better results for both datasets, i.e.,
the MedLine and DrugBank.
Table 13 shows the result of adding the Wiki source into word2vec training in
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providing the vector of word representation. These results confirm that the addition of
training data will improve the performance. It might be due to the fact that most of the
targeted token such as drug name, are uncommon words, whereas the words that are
used in Wiki’s sentence are commonly used words. Hence, the addition of commonly
used words will make the difference between drug token and the non-drug token (the
commonly used token) becomes greater. For the MLP-NN experimental results, the 4th
scenario, i.e the second data representation with 2/3 partition data selection in
Drugbank dataset, provides the best performance with 0.684646757 in F-score.
Table 12. The F-score performance as an impact of data representation technique
dataset (1)One Seq. of all sentences (2)One Seq. of each Sentence
MedLine Prec Rec F-score Prec Rec F-score
(1) 0.3564 0.5450 0.4310 0.6515 0.6220 0.6364
(2) 0.3806 0.5023 0.4331 0.6119 0.7377 0.6689
(3) 0.3772 0.5266 0.4395 0.6143 0.656873 0.6348
DrugBank Prec Rec F-score Prec Rec F-score
(1) 0.6438 0.5337 0.5836 0.7143 0.4962 0.5856
(2) 0.6438 0.6398 0.6418 0.7182 0.5804 0.6420
(3) 0.6306 0.5380 0.5807 0.5974 0.5476 0.5714
Table 13. The F-score performances as an impact of the Wiki addition of word2vec
training data
dataset (1)One Seq. of all sentences (2)One Seq. of each Sentence
MedLine Prec Rec F-score Prec Rec F-score
(1) 0.5661 0.4582 0.5065 0.614 0.6495 0.6336
(2) 0.5661 0.4946 0.5279 0.5972 0.7454 0.6631
(3) 0.5714 0.4462 0.5011 0.6193 0.6927 0.6540
DrugBank Prec Rec F-score Prec Rec F-score
(1) 0.6778 0.5460 0.6047 0.6973 0.6107 0.6511
(2) 0.6776 0.6124 0.6433 0.6961 0.6736 0.6846
(3) 0.7173 0.5574 0.6273 0.6976 0.6193 0.6561
3.2.2 DBN & SAE Performance
In the second experiment, which involves DBN and SAE learning model, we only use
the experiment scenario that gives the best results in the first experiment. The best
experiment scenario uses the second data representation technique with Wiki text as an
additional source in the word2vec training step.
In the DBN experiment, we use two stacked RBMs with 500 nodes of visible unit,
100 nodes of the hidden layer for the first and also the second RBMs. The used learning
parameters are as follows: momentum = 0; and alpha= 1. We used mini-batch scenario
in the training, with the batch size of 100. As for RBM constraints, the range of input
data value is restricted to [0..1] - as the original RBM, which is developed for binary
data type -, whereas the range of vector of word value is [−1..1]. So we normalize the
data value into [0..1] range before performing the RBM training. In the last layer of
DBN, we use one layer of MLP with 100 hidden nodes and 6 output nodes with softmax
output function as classifier.
The used SAE architecture is two stacked AEs with the following nodes configuration.
The first AE has 500 units of visible unit, 100 hidden layers, 500 output layer. The
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Figure 8. The Global LSTM Network
second AE has 100 nodes of visible unit, 100 nodes hidden unit, and 100 nodes output
unit. The used learning parameters for first SAE and the second SAE respectively are
as follows: activation function = sigmoid and tanh; learning rate = 1 and 2; momentum
= 0.5 and 0.5; sparsity target = 0.05 and 0.05. The batch size of 100 is set for both of
AEs. In the SAE experiment, we use the same discriminative layer as DBN i.e. one
layer MLP with 100 hidden node and 6 output nodes with softmax activation function.
The experiments results are presented in Table 14. There is a difference in
performances when using the MedLine and the DrugBank datasets when feeding them
into MLP, DBN, and SAE models. The best results for the MedLine dataset is obtained
when using the SAE. For the DrugBank, the MLP gives the best results. The DBN
gives lower average performance for both datasets. The lower performance is probably
due to the normalization on the word vector value to [0...1], whereas their original value
range is in fact between [−1..1]. The best performance for all experiments 1 and 2, is
given by SAE, with the second scenario of candidate selection as described in the
Subsection 2.6. Its F-score is 0.686192469.
Table 14. Experimental results of three NN-Model
dataset MLP DBN SAE
MedLine Prec Rec F-score Prec Rec F-score Prec Rec F-score
(1) 0.6515 0.6220 0.6364 0.5464 0.6866 0.6085 0.6728 0.6214 0.6461
(2) 0.5972 0.7454 0.6631 0.6119 0.7377 0.6689 0.6504 0.7261 0.6862
(3) 0.6193 0.6927 0.6540 0.6139 0.6575 0.6350 0.6738 0.6518 0.6626
Average 0.6227 0.6867 0.6512 0.5907 0.6939 0.6375 0.6657 0.6665 0.6650
DrugBank Prec Rec F-score Prec Rec F-score Prec Rec F-score
(1) 0.6973 0.6107 0.6512 0.6952 0.5847 0.6352 0.6081 0.6036 0.6059
(2) 0.6961 0.6736 0.6847 0.6937 0.6479 0.6700 0.6836 0.6768 0.6802
(3) 0.6976 0.6193 0.6561 0.6968 0.5929 0.6406 0.6033 0.6050 0.6042
Average 0.6970 0.6345 0.664 0.6952 0.6085 0.6486 0.6317 0.6285 0.6301
3.2.3 LSTM Performance
The global LSTM network used is presented in Figure 8. Each single LSTM block
consists of two stacked hidden layers, one input node with each input dimension is 200
as described in Subsection 2.4.3. All hidden layers are fully connected. We used sigmoid
as an output activation function, which is the most suitable for binary classification. We
implemented a peepholes connection LSTM variant where its gate layers look at the cell
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state [9]. In addition to implementing the peepholes connection, we also use a coupled
of forget and input gates. The detail single LSTM architecture and its each gate
formula computation can be referred in [23].
The LSTM experiments were implemented with several different parameter settings.
Their results presented in this section are the best among all our experiments. Each
input data consists of two components, its word vector value and its Euclidian distance
to the previous input data. In treating both input data components, we adapt the
Adding Problem Experiment as presented in [15]. We use the Jannlab tools [24] with
some modifications in the part of entry to conform with our data settings.
The best achieved performance is obtained with LSTM block architecture of one
node input layer, two nodes hidden layer, and one node output layer. The used
parameters are: learning rate = 0.001, momentum = 0.9, and epoch = 30, input
dimension = 200, and with the time sequence frame set to 2. The complete treatment of
drug sentence as a sequence both in representation and recognition, to extract the drug
name entities, is the best technique, as shown by F-score performance in Table 15.
Table 15. The F-score performance of third data representation technique with RNN-
LSTM
Prec Rec Fscore
MedLine 1 0.6474 0.7859
DrugBank 1 0.8921 0.9430
Average 0.8645
As described in previous work section, there are many approaches related to drug
extraction have been proposed. Most of them utilize certain external knowledge to
achieve the extraction objective. The Table 16 summarizes their F-score performance.
Among the state of the arts, our third data representation technique applied to the
LSTM model is outperforming. Also, our proposed method does not require any
external knowledge.
Table 16. The F-score performance compared to the state of the art
Approach F-score Remark
Approach F-score Remark
The Best of SemEval 2013 [31] 0.7150 -
[10] 0.5700 With external knowledge, ChEBI
[30]+Wiki 0.7200 With external knowledge, DINTO
[1] 0.7200 Additional feature, BIO
[2] 0.6000 Single token only
MLP-SentenceSequence+Wiki(average)/Ours 0.6580 Without external knowledge
DBN-SentenceSequence+Wiki(average)/Ours 0.6430 Without external knowledge
SAE-SentenceSequence+Wiki(average)/Ours 0.6480 Without external knowledge
LSTM-AllSentenceSequence+Wiki+ 0.8645 Without external knowledge
EuclidianDistance(average)/Ours
3.3 Drug Label Dataset Performance
As additional experiment, we also use Indonesian language drug label corpus to evaluate
the method’s performance. Regarding the Indonesian drug label, we could not found
any certain external knowledge that can be used to assist the extraction of the drug
name contained in the drug label. In the presence of this hinderance, we found our
proposed method is more suitable than any other previous approaches. As the drug
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label texts are collected from various sites of drug distributors, producers, and
government regulators; it does not clearly contain training data and testing data as in
DrugBanks or Medline datasets. The other characteristics of these texts are the more
structured sentences contained in the data. Although the texts are coming from various
sources, all of them are similar kind of document (the drug label that might be
generated by machine). After the data cleaning step (HTML tag removal, etc.), we
annotated the dataset manually. The total quantity of dataset after performing the data
representation step, as described in Subsection 2.4, is 1.046.200. In this experiment, we
perform 10 times cross-validation scenario by randomly selecting 80% data for the
training data and 20% data for testing.
The experimental result for drug label dataset shows that all of the candidate
selection scenarios provide excellent F-score (above 0.9). The excellent F-score
performance is probably due to the more structured sentences in those texts. The best
result of those ten experiments are presented in Table 17.
3.4 Choosing The Best Scenario
In the first and second experiments, we studied various experiment scenarios, which
involves three investigated parameters: additional Wiki source, data representation
techniques, and drug target candidate selection. In general, the Wiki addition
contributes in improving the F-score performance. The additional source in word2vec
training enhances the quality of the resulted word2vec. Through the addition of
common words, from Wiki, the difference between the common words and the
uncommon words i.e drug name becomes greater (better distinguishing power).
One problem in mining drug name entity from medical text is the imbalanced
quantity between drug token and other tokens [31]. Also, the targeted drug entities are
only a small part of the total tokens. Thus, majority of tokens are noise. In dealing
with this problem, the second and third candidate selection scenarios show their
contribution to reduce the quantity of noise. Since the possibility to extract the noises is
reduced then the recall value and F-score value increase as well, as shown in the first
and second experiments results.
The third experiment which uses LSTM model does not applied the candidate
selection scenario because the input dataset is treated as sentence sequence. So the
input dataset can not be randomly divide (selected) as the tuple treatment in the first
and second experiments.
Table 17. The best performance of 10 executions on Drug Label Corpus
Iteration Prec. Recall F-score
1 0.9170 0.9667 0.9412
2 0.8849 0.9157 0.9000
3 0.9134 0.9619 0.9370
4 0.9298 0.9500 0.9398
5 0.9640 0.9570 0.9605
6 0.8857 0.9514 0.9178
7 0.9489 0.9689 0.9588
8 0.9622 0.9654 0.9638
9 0.9507 0.9601 0.9554
10 0.9516 0.9625 0.9570
Average 0.93081 0.9560 0.9431
Min 0.8849 0.9157 0.9000
Max 0.9640 0.9689 0.9638
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4 Conclusion & Future Works
This study proposes a new approach in the data representation and classification to
extract drug name entities contained in the sentences of medical text documents. The
suggested approach solves the problem of multiple tokens for a single entity that
remained unsolved in previous studies. This study also introduces some techniques to
tackle the absence of specific external knowledge. Naturally, the words contained in the
sentence follow a certain sequence patterns, i.e., the current word is conditioned by
other previous words. Based on the sequence notion, the treatment of medical text
sentences which apply the sequence NN model, gives better results. In this study, we
presented three data representation techniques. The first and second techniques treat
the sentence as a non-sequence pattern which is evaluated with the non-sequential NN
classifier (MLP, DBN, SAE), whereas the third technique treats the sentences as a
sequence to provide data that is used as the input of the sequential NN classifier i.e.
LSTM. The performance of the application of LSTM models for the sequence data
representation, with the average F-score being 0.8645, rendered the best result
compared to the state of the art.
Some opportunities to improve the performance of the proposed technique are still
widely opened. The first step improvement can be the incorporation of additional
handcrafted features - such as the words position, the use of capital case at the
beginning of the word, the type of character - as also used in the previous studies [3, 30].
As presented in the MLP experiments for drug label document, the proposed methods
achieved excellent performance when applied to the more structured text. Thus, the
effort to make the sentence of the dataset, i.e., DrugBank and MedLine, to be more
structured can also be elaborated. Regarding the LSTM model and the sequence data
representation for the sentences of medical text, our future study will tackle the multiple
entity extractions such as drug group, drug brand, and drug compounds. Another task
that is potential to be solved with the LSTM model is the drug – drug interaction
extraction. Our experiments also utilizes the Euclidean distance measure in addition to
the word2vec features. Such addition gives a good F-score performance. The significance
of embedding the Euclidean distance features, however, needs to be explored further.
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